Novel coronavirus vaccine based on stem cells modified by acantha protein genes
The invention relates to the technical field of vaccines and discloses a novel coronavirus vaccine based on stem cells modified by acantha protein genes. An active ingredient of the novel coronavirus vaccine is mesenchymal stem cells modified by the acantha protein genes in a trimer form, and the novel coronavirus vaccine can be applied to prevention of novel coronaviruses. Meanwhile, the invention discloses a preparation method of the novel coronavirus vaccine based on the stem cells modified by the acantha protein genes. The preparation method comprises the following steps: constructing an adenovirus vector for expressing an acantha protein, preparing acantha protein recombinant adenovirus particles, purifying and enriching the adenovirus particles, obtaining mesenchymal stem cells, and obtaining human umbilical cord mesenchymal stem cells modified by an acantha protein coding gene. According to the vaccine, immune response of a human body to the novel coronaviruses is started through expressing an acantha protein by gene recombination type mesenchymal stem cells of the acantha protein, a virus neutralizing antibody is generated, therefore, infection of the virus to the human body is avoided, the vaccine is safe, reliable and effective and has a good application prospect, and a brand new choice is provided for preventing the novel coronaviruses..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Europäisches Patentamt - (2021) vom: 31. Dez. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
ZHANG JIANLI [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2021-12-31, Last update posted on www.tib.eu: 2022-08-17, Last updated: 2023-02-09 |
|---|
| Patentnummer: |
CN113855794 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA013091964 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA013091964 | ||
| 003 | DE-627 | ||
| 005 | 20230504095103.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230215s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA013091964 | ||
| 035 | |a (EPA)CN113855794 | ||
| 035 | |a (EPA)78982067 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a ZHANG JIANLI |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Novel coronavirus vaccine based on stem cells modified by acantha protein genes |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2021-12-31, Last update posted on www.tib.eu: 2022-08-17, Last updated: 2023-02-09 | ||
| 520 | |a The invention relates to the technical field of vaccines and discloses a novel coronavirus vaccine based on stem cells modified by acantha protein genes. An active ingredient of the novel coronavirus vaccine is mesenchymal stem cells modified by the acantha protein genes in a trimer form, and the novel coronavirus vaccine can be applied to prevention of novel coronaviruses. Meanwhile, the invention discloses a preparation method of the novel coronavirus vaccine based on the stem cells modified by the acantha protein genes. The preparation method comprises the following steps: constructing an adenovirus vector for expressing an acantha protein, preparing acantha protein recombinant adenovirus particles, purifying and enriching the adenovirus particles, obtaining mesenchymal stem cells, and obtaining human umbilical cord mesenchymal stem cells modified by an acantha protein coding gene. According to the vaccine, immune response of a human body to the novel coronaviruses is started through expressing an acantha protein by gene recombination type mesenchymal stem cells of the acantha protein, a virus neutralizing antibody is generated, therefore, infection of the virus to the human body is avoided, the vaccine is safe, reliable and effective and has a good application prospect, and a brand new choice is provided for preventing the novel coronaviruses. | ||
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a bio | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a ZENG QIONG |4 aut | |
| 700 | 0 | |a HUO KAIBING |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2021) vom: 31. Dez. |
| 773 | 1 | 8 | |g year:2021 |g day:31 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/78982067/publication/CN113855794A1?q=CN113855794 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | u | w | |j 2021 |b 31 |c 12 |
| 951 | |a AR | ||
| 952 | |j 2021 |b 31 |c 12 | ||